Aix-en-provence, France
Aix-en-provence, France
SEARCH FILTERS
Time filter
Source Type

Fondée en 2005 et basée à Aix-en-Provence (France), SuperSonic Imagine est une entreprise spécialisée dans le secteur de l’imagerie médicale. La société conçoit, développe et commercialise une plateforme échographique nouvelle génération, Aixplorer®, qui exploite une technologie UltraFast™ avec une cadence d’acquisition environ 200 fois plus rapide que les systèmes concurrents. Aixplorer® est le seul échographe à pouvoir imager deux types d’ondes : les ondes ultrasonores permettant de construire des images d’une qualité exceptionnelle ; les ondes de cisaillement permettant aux médecins de visualiser et analyser en temps réel la dureté des tissus, grâce à une procédure fiable, reproductible, et non invasive. Cette innovation, l’Elastographie ShearWave™, améliore la détection et la caractérisation de multiples pathologies dans de nombreuses applications, notamment le sein, la thyroïde, le foie ou la prostate. SuperSonic Imagine dispose des autorisations règlementaires nécessaires pour une commercialisation d’Aixplorer® sur les principaux marchés. Au cours des dernières années, SuperSonic Imagine a bénéficié du soutien de plusieurs investisseurs de premier plan, parmi lesquels Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital, NBGI.


Attendees to see the powerful 60-second non-invasive liver exam performed using SuperSonic Imagine's Aixplorer with ShearWave Elastography™ technology AIX-EN-PROVENCE, FRANCE--(Marketwired - May 4, 2017) - SuperSonic Imagine ( : SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today that it will showcase its Aixplorer® platform with real-time ShearWave™ Elastography (SWE™) for the assessment and management of liver diseases at Digestive Disease Week (DDW) Annual Meeting 2017, held May 6 - 9 at McCormick Place in Chicago. Accompanying SuperSonic Imagine will be Diversatek Healthcare, the exclusive distributor of Aixplorer® to Gastroenterologists and Hepatologists in the U.S.A. SuperSonic Imagine and Diversatek Healthcare will be exhibiting during DDW 2017 in the Exhibit Hall at booth #1921. "At SuperSonic Imagine, innovation in liver imaging is a driving passion, so we are thrilled to attend DDW once again and share the clinical benefits of the Aixplorer's SWE technology with specialists from around the world," said Jacques Souquet, Founder and Chief Innovation Officer at SuperSonic Imagine. "With our distribution partner, we are committed to expanding our footprint in the U.S.A., Diversatek Healthcare shares our goal of managing chronic Liver Disease with non invasive diagnostic liver imaging and quantification to assist in diagnosis. At our booth, attendees can see firsthand how SWE technology promises to do just that." "Our mission is to bring our customers in Gastroenterology and Hepatology the latest technologies to improve patient care," said Stuart Wildhorn, Chief Scientific Officer, Diversatek Healthcare. "The Aixplorer platform with SWE technology truly changes the landscape of liver disease management, making it an excellent fit for our customers and our company. Being able to visualize what you are measuring adds to better patient management." Real-time ShearWave Elastography (SWE), available only on the Aixplorer system, is a 60-second non-invasive exam used for imaging chronic liver disease. SWE offers the advantage of real-time imaging of liver anatomy, while also providing not only a color-coded map of liver stiffness, but also a quantification tool for the measurement of stiffness which is an important parameter for liver diagnostic. Over 100 peer reviewed publications have demonstrated the reliability and effectiveness of SuperSonic Imagine's SWE in imaging liver pathologies. Recently, the results of an international multicenter study on 1134 patients were published in Hepatology, and confirmed the benefit of SWE in the non-invasive assessment of liver stiffness1, including for patients with diseases such as hepatitis C that may require repeated follow-up evaluations. Although biopsy has been considered the standard for assessing liver fibrosis severity, the drawbacks of this invasive approach include significant incidence of morbidity, high procedure costs due to longer hospitalisation, and clinical shortcomings. Stiffness is even sometimes underestimated in 10-30% of cases.2,3 1 Herrmann E. 2D-Shear Wave Elastography Is Equivalent or Superior to Transient Elastography for Liver Fibrosis Assessment: Results from an Individual Patient Data Based Meta-analysis. The International Liver Congress, Vienna, April 23, 2015. 2 Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Regev A, Berho, M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Am J Gastroenterol. 2002 Oct;97(10):2614-8. 3 Sources of variability in histological scoring of chronic viral hepatitis. Rousselet MC, Michalak S, Dupré F, Croué, A, Bedossa P, Saint-André JP, Calès P; Hepatitis Network 49. Hepatology. 2005 Feb;41(2):257-64. About Diversatek Healthcare Headquartered in Milwaukee, Wisconsin, Diversatek Healthcare is a wholly-owned subsidiary of Diversatek Inc. A leader in gastroenterological medical devices and diagnostics, Diversatek Healthcare's tenured management team is committed to making business personal again through a hands-on approach to understanding clinical and patient needs. Diversatek Healthcare is driving science in the GI space while providing comprehensive educational offerings through Diversatek University, including on-site training and virtual platforms. The company offers an extensive range of state-of-the-art diagnostic and therapeutic GI applications from esophageal dilators and endoscopic accessories to high-resolution impedance manometry systems and impedance/pH total reflux monitoring. Diversatek Inc. recently united two complementary subsidiaries, Sandhill Scientific and Medovations, to form one singular organization committed to technologies that simplify the complex medical marketplace. For additional information, visit www.diversatekhealthcare.com or contact us at 800-558-6408. Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler, Angio PL.U.S - Planewave UltraSensitive™ Imaging and more recently TriVu. ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.


THERACLION (Paris:ALTHE) (Alternext, FR0010120402 - ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced its sales for 2017 first half, ended June 30, 2017. David Caumartin, CEO of Theraclion, declares: « Theraclion accelerates its growth in the first half of 2017 with the signature of 11 commercial agreements1 compared with 5 the previous year over the same period. Germany, where several health insurances already reimburse the procedure, remains the main market for the company. In the first half of the year, the continuing expansion of the number of insurance companies covering the use of echotherapy has driven growth in treatment volumes and allowed the signature of three new commercial agreements. Three orders are registered in new countries, reflecting the growing adoption of our echotherapy solution. Given this dynamic commercial development, Theraclion expects to double the number of commercial agreements1 concluded in 2017 compared to 2016. » New orders: already 11 commercial agreements1 signed during 2017 first half During the first half of 2017, the Company recorded 11 commercial agreements1: 8 Echopulse® orders, 2 of which have been already transferred2, and 3 contracts for the provision of equipment against pay per use, including 1 in Hong Kong. Equipment rent decreased compared to the first half of 2016 due to the exercise of the Echopulse purchase option at two of the three sites leasing Echopulse at the end of the 2016 financial year. While the number of clinical routine treatments increased by 77%, the sale of consumables decreased by 7% compared to the first half of 2016. As the supply chain matures and the delivery time reduces, customers are maintaining lower inventory levels than they did in 2016. The increase in service sales reflects the subscription of maintenance contracts for systems that have come out of the warranty period. Clinical routine: 77% growth in the number of treatments performed The total number of treatments increased by 52% in the first half. The number of clinical routine treatments (i.e.: treatments outside a Theraclion-sponsored clinical trial) increased by 77%, reflecting the growing clinical adoption of echotherapy. In Germany, the leading country in terms of number of treatment sites, routine clinical treatment volume increased by 89%. FDA Authorization to Start U.S. Trial for Immunotherapy and Echotherapy Combination in Breast Cancer Treatment The University of Virginia (UVA), one of Theraclion’s long-term academic partner, has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with a new clinical study. This study aims at evaluating the potential of treatment combining echotherapy delivered with Theraclion’s Echopulse (also known as High Intensity Focused Ultrasound, HIFU) with pembrolizumab, an immunotherapy drug targeting PD-1 checkpoint Inhibitor. UVA has been equipped with Theraclion’s Echopulse® since 2014. Echopulse is being evaluated in a feasibility study in the US for non-invasive treatment of breast fibroadenomas. Immunotherapy stimulates the body’s own immune system to fight tumor cells. HIFU, which has already demonstrated its efficacy in the treatment of malignant and benign tumors, could have a major impact on the efficacy of immunotherapy when delivered as a combined treatment as it may locally potentiate the immune response induced by the combined treatment of drugs and HIFU. Theraclion also announces that it has obtained new funding under its TUCE project in collaboration with SuperSonic Imagine (Euronext: SSI, FR0010526814, eligible for PEA-PME). The TUCE project aims to combine the technology of echotherapy with SuperSonic Imagine’s innovative imaging solution of. The effect of the treatment on the tissues can be monitored and validated in real time. This new funding of € 1,036,000 in July from Bpifrance, in the form of recoverable advances of € 703,000 and grants of € 333,000, follows on the € 433,000 received in July 2016. This new funding rewards a key milestone in development that includes the results of clinical trials in Europe and the FDA authorization of the launch of breast fibroadenoma trials in the United States. «We are delighted to see the advances of TUCE project, which is being promoted by Theraclion as part of our “Industrial Strategic Innovation” program. We support the future champions of the French industry and today we renew our support for Theraclion, which is developing an innovative medical device for the non-invasive treatment of tumors. We look forward to the success of the first treatments», says Nicole Tannières, Head of Follow-up of projects to the Bpifrance Expertise Department. Theraclion continue its funding efforts to secure its cash needs for 2018. About Theraclion Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com. 1 Commercial agreements cover sales of equipment and the provision of equipment for which Theraclion invoices either rent or "on a fee" basis. 2 These sales of equipment include a return clause within 12 months. This practice is commonly used by Theraclion to facilitate the adoption of its innovative technology. To date, no customer has exercised this clause. 3 These sales of equipment include a return clause within 12 months. This practice is commonly used by Theraclion to facilitate the adoption of its innovative technology. To date, no customer has exercised this clause.


News Article | July 31, 2017
Site: www.businesswire.com

Pour Michèle Lesieur, Directrice Générale de SuperSonic Imagine : « Depuis 2009, SuperSonic Imagine est avant-gardiste dans l’imagerie médicale avec son échographe Aixplorer® et son architecture révolutionnaire, exclusivement logicielle. SuperSonic Imagine a toujours été à la pointe de l’innovation en proposant continuellement de nouveaux modes d’imagerie, de plus en plus performants, pour une meilleure prise en charge des patients ». Avec la version Ultimate, la puissance de calculs a été accrue d’un facteur 4,5 en comparaison des modèles précédents. Aixplorer® Ultimate offre également un nouveau look et une nouvelle interface utilisateur, plus sobre, plus simple et plus intuitive. Le confort d’usage s’en trouve grandement augmenté, surtout après une utilisation prolongée. Cette nouvelle version inclut également la dernière née des innovations UltraFast™, Needle PL.U.S, qui permet de visualiser simultanément les structures anatomiques, les aiguilles de biopsie et de prédire leur trajectoire en temps réel avec une très grande précision. Ce nouveau mode innovant vient s’ajouter aux autres modes introduits par SuperSonic Imagine depuis 8 ans : l’élastographie ShearWave™ (SWE™) permettant de visualiser et de mesurer en temps réel la dureté des tissus sur une cartographie couleur, le Doppler UltraFast combinant en une seule acquisition Doppler Pulsé et Doppler Couleur, Angio PL.U.S. offrant une résolution inégalée pour imager la micro-vascularisation des lésions et TriVu (Mode-B + SWE + Color+) nouveau mode triplex combinant trois informations diagnostiques en un seul examen. Toutes ces innovations ont pour objectif de donner accès à de nouvelles informations diagnostiques de manière rapide et fiable. Ces nouvelles informations diagnostiques sont devenues indispensables pour le diagnostic et l’évaluation de pathologies majeures telles que les maladies chroniques du foie, les cancers du sein et ceux de la prostate. Pour Jacques Souquet, Co-Fondateur, Directeur de l’Innovation de SuperSonic Imagine : « L’Aixplorer® Ultimate est le fruit de 8 ans de Recherche et Développement, c’est un échographe, toujours plus fiable, plus rapide et innovant pour répondre aux nouveaux besoins d’imagerie dans le dépistage, le diagnostic et le suivi thérapeutique de pathologies majeures telles que le cancer du sein, de la prostate ou les hépatopathies chroniques. Avec plus de 300 publications, l’élastographie ShearWave (SWE™) a démontré ses bénéfices cliniques relatifs à l’amélioration de la détection et la caractérisation de multiples pathologies dans un large spectre d’applications ». Pour le sein, Aixplorer® Ultimate aide à mieux identifier les lésions malignes ou bénignes et de réduire le nombre de biopsies négatives Les bénéfices de l’élastographie ShearWave pour le diagnostic des lésions mammaires ont été démontrés dans plus de 100 publications parues dans des journaux à comité de lecture, dont une étude internationale menée chez plus de 1.600 patients.1-2 En associant cette technologie à une échographie conventionnelle, les diagnostiques sont plus précis et réduisent significativement le nombre de faux cas positifs, et donc les biopsies inutiles. Pour le foie, Aixplorer® Ultimate évalue les niveaux de fibrose et NASH sans biopsies L’élastographie ShearWave (SWE) permet de quantifier la dureté du foie de manière non-invasive. Ce paramètre – la dureté du foie – est déterminant pour le diagnostic, l’évaluation et le suivi des fibroses hépatiques. C’est pourquoi plus de 100 publications internationales s’accordent pour démontrer la fiabilité et l’efficacité de cette technologie dans ce domaine. Très utilisé également dans en imagerie musculo-squelettique pour visualiser les muscles, les tendons, les ligaments et les articulations afin diagnostiquer et suivre les tendinopathies. Aixplorer® avec sa technologie UltraFast est également très performant dans les examens vasculaires et en radio pédiatrie. 1 ShearWave Elastography for breast masses is highly reproducible. Cosgrove DO et al. European Radiology 2011 Dec 31 2 Shear-wave Elastography Improves the Specificity of Breast US: The BE1 Multinational Study of 939 Masses Radiology (2012 Feb;262(2):435-449) by Wendie A. Berg, MD, PhD, et al. Radiology. 2012 Feb;262(2):435-49. doi: 10.1148/radiol.11110640. Eur Radiol. 2012 May; 22(5): 1023–1032. À propos de SuperSonic Imagine Fondée en 2005 et basée à Aix-en-Provence (France), SuperSonic Imagine est une entreprise spécialisée dans le secteur de l’imagerie médicale. La société conçoit, développe et commercialise une plateforme échographique révolutionnaire, Aixplorer®, qui exploite une technologie UltraFast™ à une cadence d’acquisition environ 200 fois plus rapide que les échographes conventionnels. Outre la qualité exceptionnelle des images ainsi obtenues, cette technologie unique a donné naissance à plusieurs innovations qui ont changé le paradigme de l’imagerie échographique : l’Élastographie ShearWave™ (SWE™), la technologie Doppler UltraFast™, Angio PL.U.S - PLanewave UltraSensitive™ Imaging et, plus récemment, TriVu. L’Élastographie ShearWave permet aux médecins de visualiser et analyser en temps réel la dureté des tissus, grâce à une procédure fiable, reproductible, et non invasive. Un paramètre important pour diagnostiquer des lésions potentiellement malignes ou autres tissus malades. A ce jour, plus de 300 publications ont démontré l’intérêt de SWE pour la prise en charge des patients dans un large éventail de maladies. Le Doppler Ultrafast combine l’imagerie des flux en couleur et le Doppler pulsé en un seul examen simple, fournissant aux médecins les résultats des deux opérations simultanément pour plus d’efficacité. La dernière innovation, Angio PL.U.S, offre un niveau supérieur d’imagerie microvasculaire grâce à l’amélioration significative de la sensibilité couleur et de la résolution spatiale tout en conservant une qualité d’image 2D exceptionnelle. SuperSonic Imagine dispose des autorisations réglementaires nécessaires pour une commercialisation d’Aixplorer® sur les principaux marchés. SuperSonic Imagine est une société cotée sur Euronext depuis avril 2014 (symbole : SSI).


News Article | July 31, 2017
Site: www.businesswire.com

SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814), a company specialising in ultrasound medical imaging, is excited to introduce the newest version of its premium ultrasound system, Aixplorer® Ultimate, the result of French research and innovation using SuperSonic Imagine’s exclusive UltraFast™ technology. UltraFast, which offers acquisition rates 200 times faster than conventional ultrasound systems, has opened up the possibility of new imaging modalities that are now used daily by physicians. “Since 2009, SuperSonic Imagine has been at the forefront of medical imaging with the Aixplorer ultrasound system and its revolutionary, software-only architecture. Our company has always been at the cutting edge of innovation, continuously developing improved imaging modalities and offering better care and treatment for patients,” said SuperSonic Imagine CEO Michèle Lesieur. The Aixplorer Ultimate incorporates new architecture boasting 4.5 times more computing power than previous Aixplorer models. It also has a new streamlined look and intuitive user interface. Ease of use has been improved dramatically, especially for extended periods of work. Ultimate also incorporates the very latest UltraFast innovation – Needle PL.U.S – enabling simultaneous visualisation of anatomical structures, biopsy needles and their trajectory with a high level of precision. This new feature sits alongside other modalities introduced over the past 8 years by SSI: ShearWave™ Elastography (SWE™), used to view and measure the stiffness of tissue in real time using color mapping; UltraFast Doppler, which combines Pulsed Doppler and Color Doppler in a single sweep; Angio PL.U.S., offering unrivalled resolution for imaging microvascularisation in lesions; and TriVu (B mode + SWE + Color+), a new triplex modality combining three types of diagnostic information into a single examination. These innovations provide fast and reliable access to diagnostic information, an essential resource for the diagnosis and assessment of major diseases such as chronic liver disease and breast and prostate cancers. Jacques Souquet, Co-Founder and Chief Innovation Officer at SuperSonic Imagine, said, “Aixplorer Ultimate is the result of 8 years of research and development. This is a much more reliable, faster and innovative ultrasound system, designed to meet new imaging needs when screening, diagnosing and monitoring major diseases. Discussed in more than 400 publications, the SWE technology employed in this system has demonstrated its clinical advantages associated with the detection and characterisation of many different diseases across a broad spectrum of applications.” In the breast, Aixplorer Ultimate helps to improve the identification of malignant or benign lesions and to reduce the number of negative biopsies. The advantages of SWE in the diagnosis of mammary lesions have been demonstrated in more than 100 publications, including an international study involving more than 1,600 patients1-2. When this technology is combined with conventional ultrasound, diagnoses can be more accurate, significantly reducing the number of false positives, and thus the number of unnecessary biopsies. In the liver, Aixplorer Ultimate can assess levels of fibrosis and NASH without a biopsy. SWE makes it possible to quantify liver stiffness in a non-invasive manner. Liver stiffness is a key parameter when diagnosing, assessing and monitoring liver fibrosis. That is why more than 100 international articles agree in demonstrating the reliability and effectiveness of this technology in this particular field. In the prostate, Aixplorer Ultimate provides effective guidance for biopsies. Clinical studies show that SWE considerably increases biopsy efficiency. Its colour mapping helps doctors target sampling and keep the number of samples to a minimum. SWE is also frequently used in musculoskeletal imaging to view muscles, tendons, ligaments and joints, for the purposes of tendinopathy diagnosis and monitoring. Aixplorer, with its UltraFast technology, is also every effective in vascular and pediatric examinations. With Aixplorer Ultimate, the most advanced version of its ultrasound platform, SuperSonic Imagine has found a way to address the clinical challenges of a wide range of clinical needs among radiologists and patients. 1 ShearWave Elastography for breast masses is highly reproducible. Cosgrove DO et al. European Radiology 2011 Dec 31 2 Shear-wave Elastography Improves the Specificity of Breast US: The BE1 Multinational Study of 939 Masses Radiology (2012 Feb;262(2):435-449) by Wendie A. Berg, MD, PhD, et al. Radiology. 2012 Feb;262(2):435-49. doi: 10.1148/radiol.11110640. Eur Radiol. 2012 May; 22(5): 1023–1032. Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWETM), UltraFast™ Doppler, Angio PL.U.S – Planewave UltraSensitiveTM Imaging and more recently TriVu. ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.


News Article | July 19, 2017
Site: www.businesswire.com

SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814, PEA-PME eligible), the highly-innovative ultrasound company, today announces its sales for the 2nd quarter and 1st half of 2017. Michèle Lesieur, CEO and President of SuperSonic Imagine, comments: “I am very pleased with our second-quarter sales performance, which enabled us to record our fourth consecutive quarter of double-digit growth and gives us confidence in our projection for the rest of the year. We recorded 16% sales growth despite less than expected sales by Gastroenterology distributor in the United States. This overall great performance was driven by particularly buoyant growth in China (+41%), which is all the more important given that China will become the world’s largest market by 2020, and in France (+32%). Our improvement was bolstered by sales of Aixplorer products, but even more so by our Service activity, a consequence of the continual increase in our installed base. Lastly, the significant success of our recent capital increase validates the rationality and feasibility of our development project, the main aim of which is to break even in terms of EBITDA by 2019.” Unaudited data Note (*): this revenue is non-recurrent by nature and is not part of the Group’s core business. SuperSonic Imagine has continued its upturn by recording a fourth straight quarter of growth, which reached +16% in each of the last three quarters. Over this 2nd quarter of 2017, the Company generated growth of +16% to €5.764 million, compared with the second quarter of 2016. At constant currency, growth was 15% between the two periods. Product sales increased by +16% to €5.122 million (vs. €4.434 million) and Service sales by +23% to €642 thousand (vs. €522 thousand). Service sales thus accounted for 11% of sales over the quarter. Over the quarter, our key markets that are China and France generated growth of +41% to €2 million (vs. €1.42 million) and +32% to €1.52 million (vs. €1.15 million) respectively, while the United States saw a decrease of 33% to €671 thousand (vs. €1.006 million) with some business slipping from the second quarter to the second half. In other areas, the EMEA and Asia zones recorded growth of +27% to €2.51 million (vs. €1.98 million) and +31% to €2.57 million (vs. €1.97 million) respectively. Altogether, over the first six months of the year, SuperSonic Imagine recorded growth of +16% to €10.29 million (vs. €8.86 million). Product sales totalled €9.03 million, giving growth of +15%, and Service sales recorded an increase of +27% to €1.26 million. Over the first half, China continued to record buoyant growth (+33% to €3.17 million vs. €2.39 million), followed by France (+18% to €2.25 million vs. €1.91 million), while the United States decreased (down 10% to €1.35 million vs. €1.50 million). In regional terms, the EMEA and Asia zones grew by +22% to €4.72 million (vs. €3.86 million) and +25% to €4.16 million (vs. €3.32 million) respectively. The Americas fell by 16% to €1.41 million (vs. €1.68 million). Once other revenue, essentially consisting of non-recurrent fees to access the Group’s technology, is taken into account, SuperSonic Imagine’s total revenue for the first half of 2017 was €10.3 million, up +9% compared with the first six months of 2016. About SuperSonic Imagine Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler, Angio PL.U.S – Planewave UltraSensitive™ Imaging and more recently TriVu. ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.


Michèle Lesieur, Présidente du Directoire de SuperSonic Imagine, commente : « Je suis très satisfaite des résultats des ventes de ce 2e trimestre qui nous permet d’aligner notre 4e trimestre consécutif avec une croissance à deux chiffres et de nous projeter sur la fin de l’année 2017 avec confiance. Nous enregistrons une croissance de nos ventes de 16%, et ce, malgré une déception des ventes de notre distributeur Sandhill aux États-Unis. Cette performance est soutenue par une forte augmentation en Chine (+41%), qui deviendra le 1er marché mondial d’ici 2020, et par une dynamique solide en France (+32%). Notre progression a été soutenue sur les ventes de Produits Aixplorer, mais l’a été encore plus sur les ventes de Services, conséquence de l’augmentation continue de notre base installée. Enfin, le franc succès de notre augmentation de capital récente valide la cohérence et la faisabilité de notre projet de développement, avec pour principal objectif d’atteindre la rentabilité opérationnelle (EBITDA) à horizon 2019. » Chiffres non audités Note (*) : ces revenus sont non récurrents par nature et ne rentrent pas dans le cadre de l’activité courante. Les ventes de Produits ont augmenté de +16% à 5,122 M€ (vs. 4,434 M€). Les ventes de Services ont progressé de +23% à 642 K€ (vs. 522 K€) et représentent 11% du chiffre d’affaires trimestriel. Sur l’ensemble de nos marchés cibles, la Chine et la France ont généré sur le trimestre une croissance respective de +41% à 2,0 M€ (vs. 1,42 M€) et de +32% à 1,52 M€ (vs. 1,15 M€). Les États-Unis ont reculé de 33% à 671 K€ (vs. 1,006 M€) où certaines affaires attendues au T2 sont décalées au 2e semestre. Plus globalement, les zones EMEA et Asie ont progressé de +27% à 2,51 M€ (vs. 1,98 M€) et +31% à 2,57 M€ (vs. 1,97 M€). Au total sur les six premiers mois de l’année, SuperSonic Imagine a enregistré une croissance de +16% à 10,29 M€ (vs. 8,86 M€). Les ventes de Produits se sont élevées à 9,03 M€, soit une croissance de +15%, et les Services ont augmenté de +27% à 1,26 M€. Sur le semestre, la Chine poursuit sa forte progression (+33% à 3,17 M€ vs. 2,39 M€), suivie par la France (+18% à 2,25 M€ vs. 1,91 M€), alors que les États-Unis ont reculé de 10% (à 1,35 M€ vs. 1,5 M€). Sur l’ensemble des régions, les zones EMEA et Asie ont progressé de +22% à 4,72 M€ (vs. 3,86 M€) et +25% à 4,16 M€ (vs. 3,32 M€). La zone Amériques a reculé de 16% à 1,41 M€ (vs. 1,68 M€). À propos de SuperSonic Imagine Fondée en 2005 et basée à Aix-en-Provence (France), SuperSonic Imagine est une entreprise spécialisée dans le secteur de l’imagerie médicale. La société conçoit, développe et commercialise une plateforme échographique révolutionnaire, Aixplorer®, qui exploite une technologie UltraFast™ à une cadence d’acquisition environ 200 fois plus rapide que les échographes conventionnels. Outre la qualité exceptionnelle des images ainsi obtenues, cette technologie unique a donné naissance à plusieurs innovations qui ont changé le paradigme de l’imagerie échographique : l’Élastographie ShearWave™ (SWE™), la technologie Doppler UltraFast™, Angio PL.U.S - PLanewave UltraSensitive™ Imaging et, plus récemment, TriVu. L’Élastographie ShearWave permet aux médecins de visualiser et analyser en temps réel la dureté des tissus, grâce à une procédure fiable, reproductible, et non invasive. Un paramètre important pour diagnostiquer des lésions potentiellement malignes ou autres tissus malades. À ce jour, plus de 300 publications ont démontré l’intérêt de SWE pour la prise en charge des patients dans un large éventail de maladies. Le Doppler UltraFast combine l’imagerie des flux en couleur et le Doppler pulsé en un seul examen simple, fournissant aux médecins les résultats des deux opérations simultanément pour plus d’efficacité. La dernière innovation, Angio PL.U.S, offre un niveau supérieur d’imagerie microvasculaire grâce à l’amélioration significative de la sensibilité couleur et de la résolution spatiale tout en conservant une qualité d’image 2D exceptionnelle. SuperSonic Imagine dispose des autorisations réglementaires nécessaires pour une commercialisation d’Aixplorer® sur les principaux marchés. SuperSonic Imagine est une société cotée sur Euronext depuis avril 2014 (symbole : SSI).


Tandis que le nombre de traitements en routine clinique augmente de 77%, la vente de consommables s’inscrit en retrait de 7% par rapport au premier semestre 2016. Au fur et à mesure que la chaîne d'approvisionnement mûrit et que les délais de livraison diminuent, les clients ne constituent plus de stocks prévisionnels comme ils l'ont fait en 2016. Le projet TUCE vise à associer la technologie d’échothérapie à la solution d’imagerie innovante de SuperSonic Imagine. L’effet du traitement sur les tissus pourra être monitoré et validé en temps réel. L’obtention de ce nouveau financement de 1 036 K€ de Bpifrance en juillet, sous forme d’avances remboursables pour 703 K€ et de subventions pour 333 K€, fait suite à celui de 433 K€ de juillet 2016. Ce nouveau financement récompense le succès d’une étape clé dans le développement qui inclut notamment les résultats des études cliniques en Europe et l’autorisation de la FDA du lancement des essais sur le fibroadénome du sein menés aux Etats-Unis. « Nous sommes ravis de constater les avancées du projet TUCE, porté par Theraclion, qui s’inscrit dans le cadre de notre programme « Innovation Stratégique Industrielle ». Nous soutenons les futurs champions de l’industrie française et nous renouvelons aujourd’hui notre soutien à Theraclion qui développe un dispositif médical innovant dans le traitement non invasif des tumeurs et nous nous réjouissons du succès des premiers traitements », déclare Nicole Tannières, Responsable de suivi de projets à la direction de l’Expertise de Bpifrance. Theraclion est une société française spécialisée dans l’équipement médical de haute technologie utilisant les ultrasons thérapeutiques. S’appuyant sur les technologies les plus avancées, Theraclion conçoit et commercialise une solution innovante d’échothérapie, l’Echopulse®, qui permet le traitement des tumeurs par Ultrasons Focalisés sous guidage échographique. Theraclion est certifiée ISO 13 485 et a reçu le marquage CE pour l’ablation non invasive des adénofibromes du sein et des nodules thyroïdiens. Localisée à Malakoff, près de Paris, Theraclion rassemble une équipe de 34 personnes dont 50% sont dédiées à la R&D et aux essais cliniques.


À propos de SuperSonic Imagine Fondée en 2005 et basée à Aix-en-Provence (France), SuperSonic Imagine est une entreprise spécialisée dans le secteur de l’imagerie médicale. La société conçoit, développe et commercialise une plateforme échographique nouvelle génération, Aixplorer®, qui exploite une technologie UltraFast™ avec une cadence d’acquisition environ 200 fois plus rapide que les systèmes concurrents. Aixplorer® est le seul échographe à pouvoir imager deux types d’ondes : les ondes ultrasonores permettant de construire des images d’une qualité exceptionnelle ; les ondes de cisaillement permettant aux médecins de visualiser et analyser en temps réel la dureté des tissus, grâce à une procédure fiable, reproductible, et non invasive. Cette innovation, l’Elastographie ShearWave™, améliore la détection et la caractérisation de multiples pathologies dans de nombreuses applications, notamment le sein, la thyroïde, le foie ou la prostate. SuperSonic Imagine dispose des autorisations règlementaires nécessaires pour une commercialisation d’Aixplorer® sur les principaux marchés. Au cours des dernières années, SuperSonic Imagine a bénéficié du soutien de plusieurs investisseurs de premier plan, parmi lesquels Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital, NBGI.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-29-2016 | Award Amount: 3.82M | Year: 2016

SOLUS is a trans-disciplinary 48-month project bringing together 9 partners: industries (4), academic and clinical institutions from 5 countries (engineers, physicists and radiologists) representing cutting-edge expertise in their fields, to develop an innovative non-invasive, point-of-care, low-cost, easy-to-operate, multi-modal imaging system (diffuse optics and ultrasounds/shear wave elastography) for high-specificity diagnosis of breast cancer, the most common female cancer in Europe. Mammographic screening is effective in reducing mortality, however the 10-year cumulative false-positive risk is 50-60%, leading to needless additional invasive procedures (e.g. biopsy). The project addresses the unmet clinical need for higher specificity in breast cancer imaging following screening by fully combining photonics with non-photonics techniques, developing and clinically validating innovative and previously unthinkable photonics concepts and components: time-domain small source-detector distance optical tomography, miniaturized picosecond pulsed laser sources, high-dynamic-range time-gated single-photons detectors to achieve unprecedented sensitivity and depth penetration. For the first time, this allows a comprehensive quantitative characterization of breast tissue including composition (water, lipids, collagen), functional blood parameters, morphologic information and mechanical parameters (stiffness). This innovative multi-parametric characterization will significantly improve the specificity of breast screening, with great impact on the quality of life of millions of European women every year, and huge savings for the healthcare systems. The strong involvement of leading industrial players at all levels in the value chain will push the European innovation process and make a significant contribution to ensuring Europes industrial leadership in the biophotonics healthcare market, while addressing one of the largest societal challenges in health and well-being.

Loading SuperSonic Imagine collaborators
Loading SuperSonic Imagine collaborators